Hikma signs Easyhaler deal with Orion
13th Feb 2017 09:23
(ShareCast News) - Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Finland's Orion for its new Easyhaler combination product for the treatment of asthma and chronic obstructive pulmonary disease. Under the terms of the agreement, Hikma has the exclusive rights
Read moreFTSE 100 movers: Rio Tinto zips higher as Reckitt Benckiser falls
10th Feb 2017 17:10
(ShareCast News) - FTSE 100 is higher on Friday afternoon thanks to a string of mining behemoths led by Rio Tinto congregating atop the risers' list, albeit offset by a motley group of fallers led by consumer goods giant Reckitt Benckiser. London's top tier index closed 0.40% higher to 7,258.75 poin
Read moreSector movers: Cyclicals bounce back, Evraz in the lead
1st Feb 2017 15:46
(ShareCast News) - There was a clear split in the market on Wednesday as cyclicals bounced back and the more defensive segments of the market were relegated to the bottom of the pile. Thus, shares in Prudential and Aviva were to be seen pacing gains among life insurers as yields on benchmark 10-year
Read moreHikma gets FDA approval for generic narcolepsy treatment
18th Jan 2017 09:29
(ShareCast News) - Hikma Pharmaceuticals' US subsidiary Roxane Laboratories has received approval from the US Food and Drug Administration for its sodium oxybate oral solution for the treatment of cataplexy - sudden loss of muscle strength - and excessive daytime sleepiness in patients with narcolep
Read moreFTSE 100 movers: Pharmaceutical stocks lead FTSE's rally
16th Dec 2016 14:11
(ShareCast News) - The FTSE 100 rose 0.11% to 7,006.73 points on Friday afternoon with pharmaceutical stocks leading the way. Hikma Pharmaceuticals, Shire and Astrazeneca rallied on a positive read-across following reports Sanofi is in advanced talks to acquire Actelion. The companies are said to b
Read moreLondon close: Miners propel FTSE 100 higher as industrial metals surge
22nd Nov 2016 16:34
(ShareCast News) - London equities ended Tuesday on a sharply higher note with major miners storming ahead in tandem with soaring industrial metals prices, and followed by a string of banks and insurers. US interest rate-touch utilities were firmly higher, too. FTSE 100 closed the session up 0.62%
Read moreHikma signs agreement with Vectura for salmeterol
22nd Nov 2016 07:18
(ShareCast News) - Hikma Pharmaceuticals has signed a development and licensing agreement with Vectura for its generic salmeterol product (VR730) for the treatment of asthma and chronic obstructive pulmonary disease. Under the terms of the agreement - which has been signed by Hikma's US affiliate, W
Read moreHikma gets shot in arm from Morgan Stanley upgrade
15th Nov 2016 11:38
(ShareCast News) - Hikma Pharmaceuticals got a shot in the arm on Tuesday as Morgan Stanley upped the stock to 'overweight' from 'equalweight' pointing to increased confidence in the pipeline and an attractive valuation. MS said its "deep dive" into Hikma's medium-term pipeline and long-term opportu
Read moreLondon close: Blue chips slide, led by gold-exposed miners amid profit-taking
10th Nov 2016 17:01
(ShareCast News) - London blue-chip stocks fell on Thursday as traders took profits stoked by Donald Trump's election win, with gold-exposed miners, pharmaceutical and US rates-sensitive utilities all flopping. The FTSE 100 ended the session down 1.21% to 6,827.98 points, somewhat out of kilter with
Read moreHikma Pharmaceuticals nudges down FY revenue guidance
10th Nov 2016 07:12
(ShareCast News) - Hikma Pharmaceuticals said on Thursday that it is currently generating "good" revenue growth, but it nudged down its full-year revenue guidance, saying it now expects it to rise by around 35% to $2bn at constant currency, down from a previous range of $2bn to $2.1bn. The injectabl
Read moreSector movers: Miners, US election-related plays lead gains
9th Nov 2016 15:17
(ShareCast News) - Steel and mining stocks led gains for another session, amid widespread gains for most base metals and coal, helped by an initial bout of weakness in the US dollar. As of 1650 GMT, the US dollar was trading higher by 0.47% to 98.32 points after having earlier hit an intra-day low a
Read moreBroker tips: Aggreko, Hikma, Croda
4th Nov 2016 13:25
(ShareCast News) - Morgan Stanley upgraded power generator company Aggreko from 'underweight' to 'equal weight' and bumped up its target price from 850p to 900p, despite orders for diesel products falling. "We retain our concerns over long-term pressures on the International power Projects (IPP) bus
Read moreNumis upgrades rating on Hikma Pharmaceutical but cuts target price
4th Nov 2016 10:12
(ShareCast News) - Numis on Friday upgraded its rating on Hikma Pharmaceutical to 'buy' from 'hold' but cut its target price to 2,350p from 2,660p. Hikma's shares have fallen 35% over the past three months and significantly underperformed UK Mid-Cap Healthcare and Global Specialty Pharma, Numis high
Read moreDirector dealings: Hikma trio building dominant stake
26th Sep 2016 15:42
(ShareCast News) - Hikma Pharmaceutical's founding family, led by including chairman and chief executive Said Darwazah, have spent another £6m buying shares in the drug maker in the last few days. Darwazah, his brother and vice chairman Mazen, and non-executive Ali Al-Hursy, who also has an equity s
Read moreMonday broker round-up
12th Sep 2016 09:24
(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac
Read more